The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine
COVID-19, Breakthrough Infection
About this trial
This is an interventional prevention trial for COVID-19 focused on measuring COVID-19, Breakthrough infection, Heterologous vaccine booster, mRNA vaccine, Protein subunit vaccine
Eligibility Criteria
Inclusion Criteria:
- Participant is willing to give written informed consent for participation in the trial.
- Participants should receive 2 doses of the AZD1222. Evidence of this will be gathered from medical history and/or medical records including the COVID-19 vaccine registration yellow card.
Exclusion Criteria:
The participant may not enter the trial if ANY of the following apply:
- Fever or evidence of upper respiratory tract infections
- Confirmed COVID-19 cases (PCR-confirmed infection or detectable anti-nucleocapsid protein IgG)
- History of anaphylaxis, severe allergic disease, or reactions likely to be exacerbated by any component of study vaccines (e.g. hypersensitivity to the active substance or any of the listed ingredients of any study vaccine).
- Malignancy requiring receipt of immunosuppressive chemotherapy or radiotherapy for treatment of solid organ cancer/hematological malignancy within the 6 months prior to enrollment.
- Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injections or venipuncture.
- Has received vaccines other than COVID-19 vaccine within one month
- Pregnancy or willingness/intention to become pregnant within 3 months post booster vaccine
- Aged < 20 years or unable to sign the informed consent
- Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study, or impair interpretation of the study data or insufficient level of language to undertake all study requirements in the opinion of the Investigators.
Sites / Locations
- Chang Gung Memorial Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Booster group 1 (BNT162b2 30ug)
Booster group 2 (mRNA-1273 50ug)
Booster group 3 (mRNA-1273 100ug)
Booster group 4 (MVC-COV1901 15ug)
The participants in this group will receive BNT162b2 30ug as the booster dose.
The participants in this group will receive mRNA-1273 50ug as the booster dose.
The participants in this group will receive mRNA-1273 100ug as the booster dose.
The participants in this group will receive MCV COVID-19 vaccine 15ug as the booster dose.